<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''-->

<!--Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].-->
{| class="wikitable" style="text-align:center; width:50%;"
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor'''
|-
|style="background-color:#F0F0F0|[[File:Bethbuchbinder.jpg|frameless|upright=0.3|center]]
|<big>[[User:Bethbuchbinder|Elizabeth Buchbinder, MD]]<br>Boston, MA</big><br>[https://www.linkedin.com/in/beth-buchbinder-2a9b994/ LinkedIn]
|-
|}
<big>If you're looking for [[cutaneous squamous cell carcinoma]] regimens, they've been moved to a separate page.</big>
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}
=Guidelines=
==[https://www.nccn.org/ NCCN]==
*[https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf NCCN Guidelines - Basal Cell Skin Cancer]

=Neoadjuvant chemotherapy=
==Bleomycin & Cisplatin {{#subobject:3ba784|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:58ad71|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://journals.lww.com/amjclinicaloncology/pages/articleviewer.aspx?year=1999&issue=02000&article=00008&type=abstract Denic 1999]
|style="background-color:#ffffbe"|Pilot, <20 patients reported
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV once per day on days 1 to 4
*[[Bleomycin (Blenoxane)]] 20 mg IV once per day on days 1 to 4

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Surgery#Surgical_resection|Surgery]]
===References===
# Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999 Feb;22(1):32-4. [http://journals.lww.com/amjclinicaloncology/pages/articleviewer.aspx?year=1999&issue=02000&article=00008&type=abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10025376 PubMed]

=Advanced or metastatic disease, all lines of therapy=

==Cisplatin & Doxorubicin {{#subobject:1ab6f6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:dd241e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/8/2/342.long Guthrie et al. 1990]
|style="background-color:#91cf61"|Non-randomized
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===References===
# '''Case series:''' Guthrie TH, Porubsky ES. Successful systemic chemotherapy of advanced squamous and basal cell carcinoma of the skin with cis-diamminedichloroplatinum III and doxorubicin. Laryngoscope. 1982 Nov;92(11):1298-9. [https://onlinelibrary.wiley.com/doi/abs/10.1288/00005537-198211000-00014 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/6890609 PubMed]
# '''Case series:''' Guthrie TH Jr, McElveen LJ, Porubsky ES, Harmon JD. Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer. 1985 Apr 15;55(8):1629-32. [https://www.ncbi.nlm.nih.gov/pubmed/4038911 PubMed]
# '''Case series:''' Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990 Feb;8(2):342-6. [http://jco.ascopubs.org/content/8/2/342.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2405109 PubMed]

==Cisplatin & Paclitaxel {{#subobject:c1f84a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:a20122|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1445-1433.2004.03130.x/abstract Jefford et al. 2004]
|style="background-color:#ffffbe"|Retrospective
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Paclitaxel (Taxol)]] 135 mg/m<sup>2</sup> IV over 3 hours once on day 1

'''21-day cycles'''

===References===
# '''Retrospective:''' Jefford M, Kiffer JD, Somers G, Daniel FJ, Davis ID. Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. ANZ J Surg. 2004 Aug;74(8):704-5. [https://onlinelibrary.wiley.com/doi/10.1111/j.1445-1433.2004.03130.x/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15315581 PubMed]

==Sonidegib monotherapy {{#subobject:PYR1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:PYV1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|Comparator
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2815%2970100-2/fulltext Migden et al. 2015 (BOLT)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|Sonidegib 800 mg
|-
|}
''In this trial, 200 mg was assessed as having a better benefit-to-risk profile than the other tested dose, 800 mg.''
====Chemotherapy====
*[[Sonidegib (Odomzo)]] 200 mg PO once per day

'''Continued indefinitely'''

===References===
# '''BOLT:''' Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Chang AL, Corn√©lis F, Lear JT, Sellami D, Dummer R. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015 Jun;16(6):716-28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2815%2970100-2/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25981810 PubMed]

==Vismodegib monotherapy {{#subobject:49aef0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e5e31b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa0905360 Von Hoff et al. 2009 (JHOC-J06131)]
|style="background-color:#ffffbe"|Phase 1, <20 pts in this dosing cohort
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278761/ Sekulic et al. 2012 (ERIVANCE BCC)]
|style="background-color:#91cf61"|Non-randomized
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362529/ Tang et al. 2012 (SHH-4685s)]
| style="background-color:#1a9851" |Randomized Phase II (E)
|Placebo
| style="background-color:#1a9850" |Reduced tumor burden
|-
|}
====Chemotherapy====
*[[Vismodegib (Erivedge)]] 150 mg PO once per day

'''Continued for up to 18 months (SHH-4685s) or indefinitely (ERIVANCE BCC)'''
===References===
# '''Phase I:''' Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009 Sep 17;361(12):1164-72. Epub 2009 Sep 2. [https://www.nejm.org/doi/full/10.1056/NEJMoa0905360 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19726763 PubMed]
## '''Update:''' LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011 Apr 15;17(8):2502-11. Epub 2011 Feb 7. [http://clincancerres.aacrjournals.org/content/17/8/2502.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5244484/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21300762 PubMed]
# '''ERIVANCE BCC:''' Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012 Jun 7;366(23):2171-9. [https://www.nejm.org/doi/full/10.1056/NEJMoa1113713 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278761/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22670903 PubMed]
## '''Update:''' Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Dirix L, Hou J, Yue H, Hauschild A; ERIVANCE BCC investigators. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015 Jun;72(6):1021-6.e8. [https://www.jaad.org/article/S0190-9622(15)01404-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25981002 PubMed]
# '''SHH-4685s:''' Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, Coppola C, Chanana AM, Marji J, Bickers DR, Epstein EH Jr. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012 Jun 7;366(23):2180-8. [https://www.nejm.org/doi/10.1056/NEJMoa1113538 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362529/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22670904 PubMed]
## '''Update:''' Tang JY, Ally MS, Chanana AM, Mackay-Wiggan JM, Aszterbaum M, Lindgren JA, Ulerio G, Rezaee MR, Gildengorin G, Marji J, Clark C, Bickers DR, Epstein EH Jr. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016 Dec;17(12):1720-1731. Epub 2016 Nov 10. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30566-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27838224 PubMed]

[[Category:Cutaneous basal cell carcinoma regimens]]
[[Category:Disease-specific pages]]
[[Category:Skin cancers]]
